All In Biotech

Drug Trial Radar · NCT06161441

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 195 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

195

Actual

Start

Jul 16, 2024

Primary completion

Aug 24, 2026

Study completion Nov 4, 2029

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Dec 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is in comparison with cemiplimab and chemotherapy as peri-operative therapy in participants with NSCLC. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * How administering the study drugs might affect quality of life

Conditions

  • Resectable Non-small Cell Lung Cancer

Interventions

  • FianlimabDrug

    Administered intravenously (IV) every 3 weeks (Q3W)

  • CemiplimabDrug

    Administered IV Q3W

  • PemetrexedDrug

    Administered IV Q3W

  • PaclitaxelDrug

    Administered IV Q3W

  • CarboplatinDrug

    Administered IV Q3W

  • CisplatinDrug

    Administered IV Q3W

  • PlaceboDrug

    Administered IV Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological complete response (pCR) as evaluated by blinded independent pathological review (BIPR) in post-treatment resected tumor samplesTime frame: Up to 24 months

Locations

123 sites in 12 countries. Site status is shown where the registry gives one.

  • Clermont Oncology Center

    Clermont, Florida

  • University of Illinois

    Chicago, Illinois

  • University of Kansas Cancer Center-Westwood

    Westwood, Kansas

  • Henry Ford Health System

    Detroit, Michigan

  • Mercy South

    St Louis, Missouri

  • University of Rochester

    Rochester, New York

  • Kaiser Permanente Northwest

    Portland, Oregon

  • Virginia Cancer Care Specialist, PC

    Fairfax, Virginia

  • Eastern Health

    Box Hill, Victoria, Australia

  • St Vincent's Hospital

    Fitzroy, Victoria, Australia

  • St John of God Murdoch Hospital

    Murdoch, Western Australia, Australia

  • Orlandi Oncologia

    Providencia, Metropolitan Region, Chile

  • Clinica Santa Maria

    Santiago, Providencia, Chile

  • Centro de Oncologia de Precision

    Las Condes, Region Metropolitana, Santiago, Chile

  • Oncocentro APYS

    Viña del Mar, Valparaiso, Chile

  • APHP - Hopital Ambroise Pare

    Boulogne-Billancourt, France

  • CHU Dijon

    Dijon, France

  • Centre Hospitalier Universitaire de Nantes Hopital Guillaume et Rene Laennec

    Nantes, France

  • Uneos - Hopital R Schuman

    Vantoux, France

  • Centre de Oncologie de Gentilly

    Nancy, Grand Est, France

  • Chi Creteil

    Créteil, Île-de-France Region, France

  • Hopital Cochin

    Paris, Île-de-France Region, France

  • Institut de Cancerologie de l'Ouest

    Saint-Herblain, Nantes, France

  • Centre Hospitalier Universitaire (CHU) Bordeaux

    Bordeaux, New Aquitaine, France

  • CHU Limoges

    Limoges, New Aquitaine, France

  • Cancer Center of Adjara

    Batumi, Georgia

  • Israeli Georgian Medical Research Clinic Helsicore

    Tbilisi, Georgia

  • Llc Todua Clinic

    Tbilisi, Georgia

  • LTD New Hospitals

    Tbilisi, Georgia

  • High Technology Medical Center, University Clinic Tbilisi

    Tbilisi, Georgia

  • Institute of Clinical Oncology

    Tbilisi, Georgia

  • JSC K. Eristavi National Center of Experimental and Clinical Surgery

    Tbilisi, Georgia

  • TIM - Tbilisi Institute of Medicine

    Tbilisi, Georgia

  • Multiprofile Clinic Consilium Medulla

    Tbilisi, Georgia

  • Klinikum Esslingen

    Esslingen am Neckar, Germany

  • Universitatsklinium Giesse

    Giessen, Germany

  • Asklepios Klinikum Harburg

    Hamburg, Germany

  • Lungenklinik Hemer

    Hemer, Germany

  • MVZ fuer Haematologie und Onkologie Rhein-Kreis GmbH

    Neuss, Germany

  • LKI LUngenfachklinik Immenhausen

    Immenhausen, Hesse, Germany

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.